PURPOSE: Cardiac resynchronization therapy (CRT) reduces symptoms and improves survival in patients with advanced heart failure (New York Heart Association (NYHA) functional class III-IV), reduced ejection fraction, and wide QRS complex. Whether CRT has the same benefit also in asymptomatic or mildly symptomatic heart failure patients is controversial. Our objective is to summarize the available evidence on the effects of CRT in asymptomatic or mildly symptomatic (NYHA I-II) heart failure patients. METHODS: We searched major web databases for randomized controlled trials of CRT in patients with mild heart failure (NYHA functional class I-II). Data regarding all-cause mortality, heart failure events, left ventricular (LV) volumes and ejection fraction, and worsening of NYHA functional class were extracted. RESULTS: We identified five trials (CONTAK-CD, MIRACLE ICD-II, REVERSE, MADIT-CRT, and RAFT) that enrolled 4,213 patients (91% with NYHA II functional class). Primary analysis excluded the CONTAK-CD, which was not specifically conducted on patients with mild heart failure. At pooled analysis, CRT decreased mortality (odds ratio (OR), 0.78 [95% confidence interval (CI)], 0.63 to 0.97; p = 0.024) and heart failure events (OR, 0.63 [95% CI, 0.52 to 0.76], p < 0.001), induced a significant LV reverse remodeling (weighted mean difference (WMD) of LV ejection fraction [Formula: see text], p = 0.015 and WMD of LV end-systolic volume index [Formula: see text], p < 0.001) and prevented the progression of heart failure symptoms (OR for worsening of NYHA functional class = 0.54 [95% CI, 0.31 to 0.93], p = 0.026). Inclusion of the CONTAK-CD did not change the results. CONCLUSIONS: Among patients with mild (NYHA II) heart failure, CRT reduces mortality and the risk of heart failure events, induces a favorable LV reverse remodeling and slows the progression of heart failure symptoms.
PURPOSE: Cardiac resynchronization therapy (CRT) reduces symptoms and improves survival in patients with advanced heart failure (New York Heart Association (NYHA) functional class III-IV), reduced ejection fraction, and wide QRS complex. Whether CRT has the same benefit also in asymptomatic or mildly symptomatic heart failurepatients is controversial. Our objective is to summarize the available evidence on the effects of CRT in asymptomatic or mildly symptomatic (NYHA I-II) heart failurepatients. METHODS: We searched major web databases for randomized controlled trials of CRT in patients with mild heart failure (NYHA functional class I-II). Data regarding all-cause mortality, heart failure events, left ventricular (LV) volumes and ejection fraction, and worsening of NYHA functional class were extracted. RESULTS: We identified five trials (CONTAK-CD, MIRACLE ICD-II, REVERSE, MADIT-CRT, and RAFT) that enrolled 4,213 patients (91% with NYHA II functional class). Primary analysis excluded the CONTAK-CD, which was not specifically conducted on patients with mild heart failure. At pooled analysis, CRT decreased mortality (odds ratio (OR), 0.78 [95% confidence interval (CI)], 0.63 to 0.97; p = 0.024) and heart failure events (OR, 0.63 [95% CI, 0.52 to 0.76], p < 0.001), induced a significant LV reverse remodeling (weighted mean difference (WMD) of LV ejection fraction [Formula: see text], p = 0.015 and WMD of LV end-systolic volume index [Formula: see text], p < 0.001) and prevented the progression of heart failure symptoms (OR for worsening of NYHA functional class = 0.54 [95% CI, 0.31 to 0.93], p = 0.026). Inclusion of the CONTAK-CD did not change the results. CONCLUSIONS: Among patients with mild (NYHA II) heart failure, CRT reduces mortality and the risk of heart failure events, induces a favorable LV reverse remodeling and slows the progression of heart failure symptoms.
Authors: William T Abraham; Westby G Fisher; Andrew L Smith; David B Delurgio; Angel R Leon; Evan Loh; Dusan Z Kocovic; Milton Packer; Alfredo L Clavell; David L Hayes; Myrvin Ellestad; Robin J Trupp; Jackie Underwood; Faith Pickering; Cindy Truex; Peggy McAtee; John Messenger Journal: N Engl J Med Date: 2002-06-13 Impact factor: 91.245
Authors: Scott D Solomon; Elyse Foster; Mikhail Bourgoun; Amil Shah; Esperanza Viloria; Mary W Brown; W Jackson Hall; Marc A Pfeffer; Arthur J Moss Journal: Circulation Date: 2010-08-23 Impact factor: 29.690
Authors: Steven A Lubitz; Peter Leong-Sit; Nowell Fine; Daniel B Kramer; Jagmeet Singh; Patrick T Ellinor Journal: Eur J Heart Fail Date: 2010-04 Impact factor: 15.534
Authors: William T Abraham; James B Young; Angel R León; Stuart Adler; Alan J Bank; Shelley A Hall; Randy Lieberman; L Bing Liem; John B O'Connell; John S Schroeder; Kevin R Wheelan Journal: Circulation Date: 2004-10-25 Impact factor: 29.690
Authors: Claudia Ypenburg; Rutger J van Bommel; C Jan Willem Borleffs; Gabe B Bleeker; Eric Boersma; Martin J Schalij; Jeroen J Bax Journal: J Am Coll Cardiol Date: 2009-02-10 Impact factor: 24.094
Authors: John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi Journal: N Engl J Med Date: 2005-03-07 Impact factor: 91.245
Authors: Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg Journal: Eur Heart J Date: 2008-09-17 Impact factor: 29.983
Authors: Juwon Kim; Sung Ho Lee; Hye Ree Kim; Tae-Wan Chung; Ji-Hoon Choi; Ju Youn Kim; Kyoung-Min Park; Young Keun On; June Soo Kim; Seung-Jung Park Journal: J Clin Med Date: 2022-04-11 Impact factor: 4.964
Authors: Pasquale Santangeli; Luigi Di Biase; Rong Bai; Rodney Horton; J David Burkhardt; Javier Sanchez; Justin Price; Andrea Natale Journal: Curr Cardiol Rev Date: 2012-11